Pixium Vision SA
PAR:ALPIX

Watchlist Manager
Pixium Vision SA Logo
Pixium Vision SA
PAR:ALPIX
Watchlist
Price: 0.3764 EUR Market Closed
Market Cap: 1.5m EUR

Pixium Vision SA
Investor Relations

Pixium Vision SA conducts research and development on retinal implants. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2014-06-19. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Bernard Gilly Ph.D.
Executive Chairman
No Bio Available
Mr. Lloyd Diamond
CEO & Director
No Bio Available
Mr. Offer Nonhoff
Chief Financial Officer
No Bio Available
Dr. Lisa C. Olmos De Koo M.D., MBA
Chief Medical Advisor and Member of the Scientific & Medical Committee
No Bio Available

Contacts

Address
ILE-DE-FRANCE
Paris
74 rue du Faubourg Saint-Antoine
Contacts